Targets › TRPM2
1 program from 1 company in 1 trial: 1 Phase 3; Oncology; next expected readout Dec 2028.
[Isoform 1]: Nonselective, voltage-independent cation channel that mediates Na(+) and Ca(2+) influx, leading to increased cytoplasmic Ca(2+) levels. Functions as a ligand-gated ion channel, gated by intracellular adenosine diphosphate ribose (ADP-ribose), Ca(2+), warm temperature, and oxidative stress. (UniProt, O94759)
Open in Phaseline: the race on TRPM2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| European Organisation for Research and Treatment of Cancer - EORTC | Ra223 alpha-emitting radium-223 dichloride targeting bone metastases | TRPM2 | Phase 3 | Prostate Cancer | Dec 2028 |
Prostate Cancer (1)
small molecule (1)
European Organisation for Research and Treatment of Cancer - EORTC (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.